CARY, N.C., April 3, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Novartis Pharmaceuticals Corporation as a limited specialty pharmacy provider for VANRAFIATM (atrasentan), for adults with immunoglobulin A nephropathy (IgAN).
“Biologics by McKesson is honored be selected as a specialty pharmacy provider for VANRAFIA,” says, Ela Lourido, vice president and general manager, Biologics by McKesson. “This therapy is key to adding to available treatment options for patients suffering from IgAN.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For more information about Vanrafia, including full prescribing information, please click here. Please click here to see the Novartis Pharmaceuticals Corporation press release.